Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2007-03-27
2007-03-27
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001650, C424S130100, C424S141100
Reexamination Certificate
active
10195426
ABSTRACT:
New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
REFERENCES:
patent: 5124471 (1992-06-01), Gansow et al.
patent: 5242679 (1993-09-01), Fritzberg et al.
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5286850 (1994-02-01), Gansoh et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6306393 (2001-10-01), Goldenberg
patent: 6451284 (2002-09-01), Raestetter et al.
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 2002/0006404 (2002-01-01), Hanna et al.
patent: 2002/0058029 (2002-05-01), Hanna
patent: WO 92/07466 (1992-05-01), None
patent: WO 98/42378 (1998-10-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 01/10461 (2001-02-01), None
Knox et al, Clinical Cancer Research, 1996, vol. 2, pp. 457-470.
Eary et al., Imaging and Treatment of B-Cell Lymphoma.The Journal of Nuclear Medicine, 31:1257-1268 (Aug. 1990).
Goldenberg et al., Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody.The Journal of Clinical Oncology, 9:548-564 (Apr. 1991).
Hnatowich et al., Patient Biodistribution of Intraperitoneally Administered Yttrium-90-labeled Antibody.The Journal of Nuclear Medicine29:1428-1434 (1988).
Kaminiski et al., Radioimmunotherapy of B-Cell Lymphoma with [131] Anti-B1 (Anti-CD20) Antibody.The New England Journal of Medicine329:459-465 (Aug. 1993).
Press et al., Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody.Journal of Clinical Oncology7:1027-1038 (Aug. 1998).
Press et al., Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support.The New England Journal of Medicine, vol. 329 (Oct. 1993).
Idec Pharmaceuticalsv.Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
Biogen Idecv.Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
Eary et al., “Imaging and Treatment of B-Cell Lymphona,”J Nucl Med, 31(8):1257-1268 (1990).
Goldenberg et al., “Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody,”J Clin Oncol, 9(4):548-64 (1991).
Hnatowich et al., “Patient Biodistribution of Intraperitoneally Administered Yttrium-90-labeled Antibody,”J Nucl Med, 29:1428-35 (1988).
Kaminiski et al., “Radioimmunotherapy of B-Cell Lymphoma with [131] Anti-B1 (Anti-CD20) Antibody,” N Engl J Med, 329:459-65 (1993).
Press et al., “Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody”,J Clin Oncol, 7(8):1027-38 (1989).
Press et al., “Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support,”N Engl J Med, 329(17):1219-24 (1993).
Maloney et al., “Newer Treatments and Non-Hodgkin's Lymphoma: Monoclonal Antibodies,”Oncology, 12(8):63-76 (1998) (first page/abstract only).
Behr et al., “Low versus high dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell associated malignancies,”Clinical Cancer Research, 5(10):3304s-3314s (1999).
Wiseman et al., “Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal anitbody,”Clinical Cancer Research, 5(10):3281s-3286s (1999).
Gopal et al., “Clinical applications of Anti-CD20 antibodies,”J Clin Med, 134(5):445-450 (1999).
Witzig et al., “Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+)B-cell non-Hodgkin's lymphoma,”J Clin Oncol, 17(12):3793-3803 (1999).
Letter from Ruta Freimanis of the United States Adopted Names Council to John Wood of IDEC Pharmaceuticals dated Sep. 25, 1996.
Wiseman et al., “Zevalin™ Biodistribution and Dosimetry Estimated Normal Organ Absorbed Radiation Doses Are Not Affected By Prior Therapy With Rituximab,” Poster presented Dec. 3-7, 1999 (abstract only); Blood, 94(10, Suppl. 1):92a, #403 (1999).
Wiseman et al., “Final Dosimetry Results of IDEC Y2B8 Phase I/II90Yttrium Radioimmunotherapy Trial in Non-Hodgkin's Lymphoma (NHL),” J. Nucl. Med., 40:64P(260) (1999, Jun. Supplement).
Wiseman et al., “IDEC-Y2B8 (90Yttrium Ibritumomab Tiuxetan) Radioimmunotherapy Safey Results in relapsed of Chemotherapy Refractory Non-Hodgkin's Lymphoma (NHL) patients Treated at Reduced Doses Because of Pre-existing Thrombocytopenia,” Poster presented Oct. 31-Nov. 4, 1999; Intl. J. Radiation Oncology, 45(3 Suppl):390 (#2217) (1999).
Wiseman et al., “90Yttrium Labeled IDEC Y2B8 Anti-CD20 Radioimmunotherapy of Non-Hodgkin's Lymphoma,” Cancer Biotherapy & Radiopharmaceuticals, 14(4):315, abstract #2 (1999).
Leget et al., “Use of rituximab, the new FDA-approved antibody,”Curr Opin Oncol, 1998, 10(6):548-551.
Matsumura et al., “Establishment and characterization of a new human B-cell line (ONHL-1) from non-Hodgkin's lymphoma: constant expression of bcl-2 gene during mitogen-induced growth inhibition,”Int J Cancer, 1990, 46(6):1107-1111 (abstract only).
McLaughlin et al., “Clinical status and optimal use of rituximab for B-cell lymphomas,”Oncology(Huntingt), 1998, 12(12):1763-1769.
Wiseman et al., “IDEC-Y2B8 radioimmunotherapy: baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry,”Blood, 1998 92(10 Suppl 1): 417a.
White et al., “Radioimmunotherapy of relapsed or refractory non-Hoggkin's lymphoma (NHL): IDEC-Y2B8 phase I/II [90]yttrium trial,” Poster presentation at VII International Conference on Malignant Lymphoma, Lugano, Switzerland,Annals of Oncol, 1999, 10 (Suppl 3): 64(215).
Kaminski, et al., “Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody,” 1990,Antibody Immunoconjugates, and Radiopharmaceuticals, vol. 3, No. 1, Abstract No. 83.
Kaminski, et al., “Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody,” 1990,Proceedings of ASCO, vol. 9, p. 271, Abstract No. 1051.
Wahl, et al., “Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody,”The Journal of Nuclear Medicine: Proceedings of the 37thAnnual Meeting, p. 852, Abstract No. 622 (1990).
Kaminski, et al., “Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma,” 1990,Antibody Immunoconjugates, and Radiopharmaceuticals, vol. 4, No. 1, p. 36, Abstract No. 66.
Kaminski, et al., “Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma,” 1990,Blood, vol. 76, No. 10, p. 355a, Abstract No. 1409.
Kaminski, et al., “Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma,” 1992,Journal of Clinical Oncology, vol. 10, No. 11, pp. 1696-1711.
Jensen, et al., “Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab),” 1998,Ann Hematol, vol. 77, pp. 89-91.
Bhagwati et al., 1998, “Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia,” Hematopathol. Mol. Hematol., 11(2):101-8 (abstract only).
Raestetter William
White Christine A.
Biogen IDEC Inc.
Jones Dameron L.
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Clinical parameters for determining hematologic toxicity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clinical parameters for determining hematologic toxicity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clinical parameters for determining hematologic toxicity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750270